Literature DB >> 17598409

Aberrant glycosylation of Igg heavy chain in multiple myeloma.

Igor Aurer1, Gordan Lauc, Jerka Dumić, Dubravko Rendić, Danica Matisić, Marija Milos, Marija Heffer-Lauc, Mirna Flogel, Boris Labar.   

Abstract

Although the majority of eukaryotic proteins are glycosylated, there is a dearth of knowledge regarding protein sugar moieties and their changes in disease. Most multiple myeloma cases are characterized by production of monoclonal immunoglobulins (Ig). We studied galactosylation and sialylation of IgG heavy chains in 16 patients with IgG myeloma using lectin blotting and densitometry. In comparison to age and sex matched controls, galactosylation was reduced in multiple myeloma (median 317 vs. 362, range 153-410 vs. 309-447 relative units, p = 0.015, Student's t-test). Sialylation was stage dependent; samples from patients with stage IIA had lowest amounts of sialic acid, IIIA intermediate and IIIB highest (142.6 vs. 185.9 vs. 248.5 relative units, correlation coefficient r = 0.55). Both galactosylation and sialylation levels were independent of age, sex, treatment type, response to treatment, disease duration and IgG and b2 microglobulin concentration. These data indicate that multiple myeloma is characterized by aberrant immunoglobulin glycosylation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17598409

Source DB:  PubMed          Journal:  Coll Antropol        ISSN: 0350-6134


  17 in total

Review 1.  IgG-Fc N-glycosylation at Asn297 and IgA O-glycosylation in the hinge region in health and disease.

Authors:  Jing Xue; Li-Ping Zhu; Qiang Wei
Journal:  Glycoconj J       Date:  2013-06-20       Impact factor: 2.916

Review 2.  Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Ema Prenc; Drazen Pulanic; Maja Pucic-Bakovic; Marija Pezer; Lana Desnica; Radovan Vrhovac; Damir Nemet; Steven Z Pavletic
Journal:  Biochim Biophys Acta       Date:  2016-02-26

3.  The history of IgG glycosylation and where we are now.

Authors:  Brian A Cobb
Journal:  Glycobiology       Date:  2020-03-20       Impact factor: 4.313

4.  Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia.

Authors:  Lukas Janker; Rupert L Mayer; Andrea Bileck; Dominique Kreutz; Johanna C Mader; Kirsten Utpatel; Daniel Heudobler; Hermine Agis; Christopher Gerner; Astrid Slany
Journal:  Mol Cell Proteomics       Date:  2019-02-21       Impact factor: 5.911

5.  Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival.

Authors:  Kristel Kodar; Johannes Stadlmann; Kersti Klaamas; Boris Sergeyev; Oleg Kurtenkov
Journal:  Glycoconj J       Date:  2011-12-17       Impact factor: 2.916

6.  Proteomics-inspired precision medicine for treating and understanding multiple myeloma.

Authors:  Matthew Ho; Giada Bianchi; Kenneth C Anderson
Journal:  Expert Rev Precis Med Drug Dev       Date:  2020-02-24

7.  Oxidative stress and DNA methylation in prostate cancer.

Authors:  Krishna Vanaja Donkena; Charles Y F Young; Donald J Tindall
Journal:  Obstet Gynecol Int       Date:  2010-06-29

8.  Multiplexed surrogate analysis of glycotransferase activity in whole biospecimens.

Authors:  Chad R Borges; Douglas S Rehder; Paolo Boffetta
Journal:  Anal Chem       Date:  2013-02-15       Impact factor: 6.986

9.  Glycan Node Analysis: A Bottom-up Approach to Glycomics.

Authors:  Sahba Zaare; Jesús S Aguilar; Yueming Hu; Shadi Ferdosi; Chad R Borges
Journal:  J Vis Exp       Date:  2016-05-22       Impact factor: 1.355

10.  Glycosylation of plasma IgG in colorectal cancer prognosis.

Authors:  Evropi Theodoratou; Kujtim Thaçi; Felix Agakov; Maria N Timofeeva; Jerko Štambuk; Maja Pučić-Baković; Frano Vučković; Peter Orchard; Anna Agakova; Farhat V N Din; Ewan Brown; Pauline M Rudd; Susan M Farrington; Malcolm G Dunlop; Harry Campbell; Gordan Lauc
Journal:  Sci Rep       Date:  2016-06-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.